drugset / Trial / NCT01978652

Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants.

NCT01978652

Phase 1 Completed 44 enrolled Biogen
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to characterise the pharmacokinetics (PK) of BIIB017 (Peginterferon Beta-1a) administered as a single 125 μg subcutaneous (SC) dose in Japanese and Caucasian adult healthy participants. The secondary Objective is to assess the safety and tolerability of a single 125 μg subcutaneous (SC) dose of BIIB017 in Japanese and Caucasian adult healthy participants.

Timeline

Start
2013-12
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject peginterferon beta-1a Protein / enzyme biologic 125 ug Subcutaneous

Indications

No indication recorded.